Septerna (SEPN) Shares Outstanding (Weighted Average) (2023 - 2026)
Septerna (SEPN) recorded quarterly Shares Outstanding (Weighted Average) of $44.8 million in Q1 2026, up 1.13% quarter-over-quarter from $44.3 million in Q4 2025, and up 1.87% on a YoY basis from $43.9 million in Q1 2025.
Septerna (SEPN) Shares Outstanding (Weighted Average) (2023 - 2026) Analysis & Trends
Septerna's Shares Outstanding (Weighted Average) history runs 4 years deep, the most recent figure standing at $44.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 1.87% year-over-year to $44.8 million; the TTM figure through Mar 2026 stood at $44.8 million (up 1.87% YoY), while the FY2025 annual figure was $44.3 million, up 347.46% from the prior year.
- Shares Outstanding (Weighted Average) was $44.8 million for Q1 2026 at Septerna, up from $44.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $44.8 million in Q1 2026 to a low of $1.9 million in Q4 2023.
- Historically, Shares Outstanding (Weighted Average) has averaged $22.0 million across 4 years, with a median of $9.9 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) surged 1868.31% in 2025, then gained 1.87% in 2026.
- A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $1.9 million in 2023, then surged by 412.87% to $9.9 million in 2024, then jumped by 347.46% to $44.3 million in 2025, then rose by 1.13% to $44.8 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $44.8 million (Q1 2026), $44.3 million (Q4 2025), and $44.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | 44.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.76 Mn |
| Dec 31, 2025 | 44.26 Mn |
| Sep 30, 2025 | 44.34 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | 43.94 Mn |
| Dec 31, 2024 | 9.89 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.23 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 2.01 Mn |